Recent biotech IPOs Iambic Therapeutics (NASDAQ: IAM) and City Therapeutics (NASDAQ: CTY) posted strong gains. Inverse leveraged ETFs SMCZ and SMST advanced as their underlying stocks declined. Iamb...
The GraniteShares 2x Long NBIS Daily ETF (NASDAQ: ...
TotalEnergies expects robust third-quarter pe...
ServisFirst Bancshares (NYSE: SFBS) is preparing to release its third-quarter 2026 earnings, with analysts projecting $0.83 per share and $173.1 million in revenue. Despite anticipated year-o
Quaker Chemical Corporation (NYSE: KWR) exhibits mixed short-term stock performance, with a recent dip potentially offering a lower entry point for investors. Analysts project a significant u
Citigroup has reiterated a Neutral rating on Travelers (NYSE:TRV) while increasing its price target to $395, reflecting a modest upside from current trading levels. Travelers reported robust
F.N.B. Corporation (NYSE: FNB) will report third-quarter 2026 results after the market closes on October 19. Analysts expect earnings of approximately $0.43 per share and revenue between $475.89 mill
Goldman Sachs analyst Neil Mehta set a $169 price target for Exxon Mobil (NYSE: XOM), suggesting a potential 4.7% downside from its then $177.30 share price. Higher refining margins are expec
Roth Capital upgraded Occidental Petroleum (NYSE: OXY) to Buy, citing potential gains from rising crude oil prices, the company’s robust resources, and substantial free cash flow. Rising oi